688029 南微医学
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)7.29614.33614.87614.21510.719
总资产报酬率 ROA (%)5.56611.13612.06311.7288.786
投入资产回报率 ROIC (%)6.67513.35714.27113.70410.467

边际利润分析
销售毛利率 (%)64.85364.09467.65364.50460.950
营业利润率 (%)21.85821.72523.93123.00118.391
息税前利润/营业总收入 (%)25.22819.63422.14020.19815.514
净利润/营业总收入 (%)17.85218.29820.61720.51416.809

收益指标分析
经营活动净收益/利润总额(%)100.436101.698104.75198.62793.493
价值变动净收益/利润总额(%)2.2722.5863.0364.92811.752
营业外收支净额/利润总额(%)0.037-0.0770.0551.8131.009

偿债能力分析
流动比率 (X)3.5663.6284.1185.0675.343
速动比率 (X)2.8923.0093.4524.2644.327
资产负债率 (%)19.10720.52818.41716.44815.910
带息债务/全部投入资本 (%)5.4406.7372.1412.1991.131
股东权益/带息债务 (%)1,696.6661,346.0214,483.7954,358.7378,580.466
股东权益/负债合计 (%)402.933368.257434.663499.910520.536
利息保障倍数 (X)7.503-9.466-12.267-6.258-5.064

营运能力分析
应收账款周转天数 (天)57.07354.87655.13751.67057.921
存货周转天数 (天)185.496182.287213.687228.962223.846